Randomized, Open, 2-way Cross Over, Single Dose Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male

Trial Profile

Randomized, Open, 2-way Cross Over, Single Dose Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs Esomeprazole/naproxen (Primary)
  • Indications Musculoskeletal pain; NSAID-induced gastrointestinal damage; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Acronyms ESNP
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 18 Mar 2014 Primary endpoint 'Peak-drug-concentration' has been met.
    • 18 Mar 2014 Primary endpoint 'Area-under-the-drug-concentration-time-curve' has been met.
    • 18 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top